Olaparib is an FDA-approved PARP inhibitor that can be used either on its own (monotherapy) or in combination with bevacizumab as a maintenance therapy for ovarian cancer. When used with bevacizumab, it's specifically for patients whose tumors have responded to platinum-based chemotherapy and who have BRCA gene mutations.
Show Full Answer
Olaparib is an FDA-approved PARP inhibitor that can be used either on its own (monotherapy) or in combination with bevacizumab as a maintenance therapy for ovarian cancer. When used with bevacizumab, it's specifically for patients whose tumors have responded to platinum-based chemotherapy and who have BRCA gene mutations.
The key benefit is that it can help delay cancer recurrence or progression. In clinical studies, women who took olaparib along with bevacizumab gained an additional 19 months before their tumors returned or got worse, particularly in those with certain genetic mutations. The medication is generally well-tolerated, with only 12% of study participants discontinuing due to side effects. While side effects can occur (most commonly anemia), regular monitoring by your healthcare team can help manage these effectively.
For best results, it's important to take the medication exactly as prescribed. If you experience any challenges with the treatment - whether related to side effects or other factors - discussing these with your healthcare team can help ensure you get the maximum benefit from the therapy.
September 25, 2025
Join
Your Privacy Choices
